Diabetic Macular Edema (DME)
5
Pipeline Programs
4
Companies
5
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
2
2
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 4 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
RegeneronTARRYTOWN, NY
2 programs1
1
Aflibercept 8 mgPhase 41 trial
aflibercept 8 mg PFSPhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
RegeneronAflibercept 8 mg
ANI PharmaceuticalsILUVIEN 0.19 MG
Regeneronaflibercept 8 mg PFS
CelltrionCT-P42
BioCryst Pharmaceuticalsavoralstat
Clinical Trials (5)
Total enrollment: 407 patients across 5 trials
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
Start: Jul 2025Est. completion: Aug 202715 patients
Phase 4Recruiting
Phase 4 IOP Signals Associated With ILUVIEN®
Start: May 2015Est. completion: Jul 2020
Phase 4Completed
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
Start: Apr 2024Est. completion: May 202435 patients
Phase 3Completed
Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema
Start: Jul 2021Est. completion: Apr 2023348 patients
Phase 3Completed
A Study of Avoralstat In Participants With Diabetic Macular Edema
Start: Oct 2025Est. completion: Sep 20269 patients
Phase 1Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 407 patients
4 companies competing in this space